TBG Diagnostics logo

TDL - TBG Diagnostics News Story

A$0.27 0.0  0.0%

Last Trade - 17/03/20

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £1.89m
Position in Universe th / 1833

BRIEF-Tbg Diagnostics Says Unit Got CE Mark Approval For Exprobetm Sars-Cov-2 Testing Kit

Thu 21st May, 2020 11:20am
May 21 (Reuters) - TBG Diagnostics Ltd  TDL.AX :
    * UNIT GOT CE MARK APPROVAL FOR EXPROBETM SARS-COV-2 TESTING
KIT &
SARS-COV-2 IGG / IGM RAPID TEST KIT
    * EXPECTS TEST TO TAKE 15 MINUTES TO COMPLETE, DETECT
PRESENCE OF
SARS- COV-2 SPECIFIC IGM & IGG ANTIBODIES IN BLOOD, SERUM &
PLASMA
    * TEST PRODUCTS EXPECTED TO BE ABLE TO CONFIRM THOSE WHO
HAVE BEEN
INFECTED BY SARS-COV-2 & GENERATED SPECIFIC ANTIBODY RESPONSE

Source text for Eikon:  urn:newsml:reuters.com:*:nASX2M0ntp
Further company coverage:  TDL.AX 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.